Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 4Terminated 1

Sponsor Class

OTHER 7INDUSTRY 5NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 3Breast 2Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 8Neoplasms 5Lymphoma, Mantle-Cell 4Breast Neoplasms 4Kidney Neoplasms 3Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma 2Urogenital Neoplasms 1Solid Tumors 1Prostatic Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × temsirolimus × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
63 enrolled 26 charts
Tumor-Agnostic

Neoplasms

NCT01378377 2018-07-30

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

EMD Serono

Phase 1 Terminated
33 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT00106353 2013-02-08

Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors

Pfizer

Phase 1/2 Completed
71 enrolled 42 charts
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT00062751 2011-04-15

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
108 enrolled 4 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡